Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Chiome Bioscience Inc.. A complete text table follows the diagram.
The filing reports a development-stage cost base and loss, with R&D the largest disclosed component.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Research And Development Expenses SGA | 1 | 396M | 58.6% of reported total |
| Other SGA | 1 | 280M | 41.4% of reported total |
| Other & rounding | 1 | 0 | 0.0% of reported total |
| Selling General And Administrative Expenses | 2 | 676M | Reported six-month total · ¥676M |
| Operating loss | 2 | 537M | Absolute value of reported operating loss |
| Operating costs & expenses | 3 | 1.2B | Revenue plus reported operating loss |
| From | To | Value |
|---|---|---|
| Research And Development Expenses SGA | Selling General And Administrative Expenses | 396M |
| Other SGA | Selling General And Administrative Expenses | 280M |
| Other & rounding | Selling General And Administrative Expenses | 0 |
| Selling General And Administrative Expenses | Operating costs & expenses | 676M |
| Operating loss | Operating costs & expenses | 537M |